Home Sectors Industrials Buy or Sell: ArcBest Corporation (NASDAQ: ARCB)

Buy or Sell: ArcBest Corporation (NASDAQ: ARCB)


ArcBest Corporation trades as part of the transportation and logistics industry and is in the industrials sector. The company CEO is Judy R. McReynolds. ArcBest Corp is a transportation company. The company provides freight transportation services and solutions. It operates through three segments namely Asset-Based, ArcBest and FleetNet.

Previous Intraday Trading Performance:

The ARCB stock showed a previous change of 1.13% with an open at 33.66 and a close of 33.99. It reached an intraday high of 34.34 and a low of 33.64.

SeekingAlpha:  ArcBest falls after BofA Merrill Lynch warning


The stock has a market cap of $868.0m with 25.5m shares outstanding, of which the float is 24.0m shares. Trading volume reached 174,334 shares compared to its average volume of 311,872 shares. Based on the current average volume and close price, the trading liquidity is bad, highly speculative and an investor may want to avoid this stock.

Historical Trading Performance:

Over the last five trading days, ArcBest Corporation shares returned 0.95% and in the past 30 trading days it returned -17.04%. Over three months, it changed -5.56%. In one year it has changed -1.46% and within that year its 52-week high was 51.45 and its 52-week low was 30.90. ARCB stock is 10.00% above its 52 Week Low.

Our calculations show a 200 day moving average of 41.99 and a 50 day moving average of 37.03. Currently ARCB stock is trading -19.05% below its 200 day moving average and may not be a good opportunity to buy as it may continue to trend down.

SeekingAlpha:  ArcBest falls after BofA Merrill Lynch warning


The last annual fiscal EPS for the company was reported at 3.86 that ended on 31st of December 2018, which according to the previous close, that is a PE of 13.54. Based on 8 analyst estimates, the consensus EPS for the next quarter is 0.92. The TTM EPS is 3.86, which comes to a TTM PE of 8.81. Historically, the PE high was 83.40 and the PE low was 8.80. If the stock reached its PE low, that would represent a price of 33.95, which is a decrease of -0.11%.

The following are the last four quarter reported earnings per share:
12-31-2018:  1.01
09-30-2018:  1.44
06-30-2018:  1.12
03-31-2018:  0.29

The dividend per share is currently 0.32, which is a dividend yield of 0.94%. Also, the payout ratio is 8.29%, therefore the dividend is safe according to our calculations.

Base on our calculations, the intrinsic value per share is 52.25, which means it is possibly undervalued and has a margin of safety of 34.95%

Indicators to Watch:

Based on the latest filings, there is 144.40% of institutional ownership. Short-interest is 0, which is 0.00% of shares outstanding. The short-interest ratio or days-to-cover ratio is 0.00.

The current calculated beta is 2.12

SeekingAlpha:  ANI Pharmaceuticals beats by $0.08, beats on revenue

Fundamental Indicators:

Based on last reported financials, the company’s return on equity is 10.01%, return on assets is 4.72%, profit margin is 2.21%, price-to-sales is 0.28 and price-to-book is 1.20.

Company Scores:

All scores are out of six:
 5  :Valuation Score
 3  :Past Performance Score
 4  :Financial Strength Score
 2  :Future Growth Score
 2  :Dividend Score
 3  :Overall Score

John Jones
Worked for several Wall Street firms: Salomon Smith Barney, UBS, and Charles Schwab. Has developed skills and gained extensive experience over the years that is used today to uncover winning penny stocks.Also was an attorney for small businesses in Scottsdale, Arizona. That experience and understanding of law provides a unique perspective and edge in discovering quality companies in various industries.